Moderate Exercise Cuts the Risk of Colorectal Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

BETHESDA, Md--"Exercise appears to be one good way, among others, to lower the risk of colorectal cancer," Maria Elena Martinez, PhD, said at the American Society of Preventive Oncology meeting. "And you don’t have to be a marathon runner to get this benefit."

BETHESDA, Md--"Exercise appears to be one good way, among others, to lower the risk of colorectal cancer," Maria Elena Martinez, PhD, said at the American Society of Preventive Oncology meeting. "And you don’t have to be a marathon runner to get this benefit."

Dr. Martinez, research assistant professor, Cancer Prevention and Control, Arizona Cancer Center, Tucson, spoke at a workshop on preventing colon cancer. She said that studies consistently show an inverse association between physical activity and colorectal cancers. The most sedentary segment of the population has an 80% greater risk of colorectal cancer than those who engage in frequent, vigorous exercise.

Mechanism Unknown

The mechanism by which exercise cuts colorectal cancer risk has not been identified, Dr. Martinez said, but there is enough evidence to posit a causal relationship. Several hypotheses have been suggested, including faster gastrointestinal transit time, improved immune function, and increased bile acid metabolism (although the bile acid hypothesis has since been discredited).

The prostaglandins have been implicated as well. Preliminary results from one study by Dr. Martinez show that reduced physical activity raises the levels of PGE2 in rectal mucosae (although not significantly), which may increase transit time.

There is also a positive association between body mass index and PGE2. "Perhaps body mass index is a marker for physical activity or perhaps there is a more direct connection," she said.

Yet another hypothesis centers on insulin resistance: Physical inactivity and abdominal obesity contribute to insulin resistance, leading to hyperinsulinemia and eventually to an increased risk of colon cancer.

Whatever the cause, Dr. Martinez suggested that a waist-to-hip ratio greater than 0.98 leads to a much higher risk in men. "This may be because when men gain weight, it is more likely to be focused in the central region, compared to women, who carry their weight lower down," she said.

There are conflicting data on the intensity of exercise required to lower colorectal cancer risk. Dr. Martinez said that low-intensity exercise has not been shown to be protective, but that moderate- and high-intensity exercise appear to be almost equally protective. Walking briskly just 6 hours a week, or jogging, swimming, or biking 3 hours a week, is sufficient. Even climbing stairs 10 minutes a day five times a week will fill one-third of the week’s exercise quota.

Related Videos
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content